Latest Financial Position News

ActivEX Limited reports a maiden gold resource of 310,000 ounces at its Gilberton project and broadens its rare earth element exploration with new tenement applications in Queensland.

Atomo Diagnostics reports strong commercial momentum in Q4 FY25, highlighted by a major US supply agreement, rapid growth in HIV self-test sales, and promising data for its syphilis test.

Spenda Limited has reported a record-breaking FY25 with cash receipts soaring 114% to $11.5 million and launched its APG Pay platform backed by a $50 million funding commitment. The company also trimmed operating costs by 39%, setting a leaner foundation for FY26 growth.

Anson Resources has announced a maiden JORC lithium resource of 103,000 tonnes LCE at its Green River Project in Utah, with plans to expand through historic well re-entry and a new collaboration with POSCO for lithium extraction technology.

Petratherm Limited has significantly expanded its Rosewood Titanium Discovery at the Muckanippie Project through Phase 2 drilling, revealing high-grade mineralisation over a 20km² area that remains open to the north. The company also completed Phase 3 drilling and strengthened its leadership with a key executive appointment.

Liontown Resources capped its first year at Kathleen Valley with over 300,000 tonnes of spodumene concentrate produced and a record $23 million in operating cash flow, despite a challenging lithium price environment. The company is on track to complete open pit mining by year-end and fully transition to underground operations by Q3 FY26.

Alpha HPA Limited has kicked off major civil works for its HPA First Project Stage 2 while securing strong sales momentum in the semiconductor sector, supported by expanded Letters of Intent covering over 60% of Stage 2 capacity.

First Lithium Limited is on the cusp of securing critical mining license renewals in Mali and anticipates releasing its maiden Mineral Resource Estimate this quarter, while managing funding and exploration cost pressures.

Clever Culture Systems advances its pharmaceutical market penetration with AstraZeneca’s full deployment and Novo Nordisk’s first order, while launching a new contact plate analysis module that doubles its APAS Independence system’s capabilities.

Imagion Biosystems has made significant progress towards filing an Investigational New Drug application for its MagSense® HER2 breast cancer imaging agent, receiving encouraging feedback from the FDA and preparing for a Phase 2 clinical trial.

Paradigm Biopharmaceuticals has advanced its global Phase 3 trial for knee osteoarthritis pain with active patient recruitment in Australia and the US, backed by a $41.2 million convertible note facility. The company also expanded its osteoarthritis portfolio through the acquisition of Proteobioactives and the Pentacoxib™ oral therapy.

Iondrive Limited advances its proprietary battery recycling technology with a pilot plant design, European consortium formation, and new e-waste initiatives, supported by significant grant funding.